Bertilimumab is a human monoclonal antibody that targets eotaxin-1, a potent chemoattractant of eosinophils and important regulator of eosinophil overall function. Bertilimumab has the potential for the treatment of allergy disorders.
BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.